September 27, 2017- BARDA awards Contract to Tangen Biosciences, Inc. to Support Development of a Rapid, Deployable, Sensitive Diagnostic Platform to Diagnose Anthrax.

BARDA awarded a $3,199,221 base period of a contract to Tangen BioSciences, Inc. of Branford, CT to further advance and expand the ability to combat the threat of Bacillus anthracis with the TangenDx Molecular Diagnostic System (TangenDx™ System), which is a rapid, sensitive, low cost, and field deployable diagnostic assay.